AbbVie successor to Humira in psoriasis gains FDA approval

With Humira set to face increasing biosimilar competition internationally this year, AbbVie notched its first U.S. approval for a successor to the blockbuster, Skyrizi (risankizumab-rzaa), late Tuesday. FDA approved the IL-23 inhibitor to treat plaque psoriasis, one of at least 10 indications on Humira adalimumab’s label.